{"id":5646,"date":"2024-02-07T09:10:31","date_gmt":"2024-02-07T15:10:31","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5646"},"modified":"2025-06-27T11:22:09","modified_gmt":"2025-06-27T16:22:09","slug":"nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la 47\u00aa reuni\u00f3n anual de la Macula Society"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><strong>Dallas, TX<\/strong> (7 de febrero de 2024) - <a href=\"https:\/\/nanostherapeutics.com\/es\/\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina, anunci\u00f3 hoy que el Dr. V\u00edctor Gonz\u00e1lez presentar\u00e1 en la <a href=\"https:\/\/www.xcdsystem.com\/maculasociety\/program\/hDy5ljm\/index.cfm\">47\u00aa Reuni\u00f3n Anual de la Sociedad de M\u00e1cula<\/a>, que tendr\u00e1 lugar del 7 al 10 de febrero en el La Quinta Resort &amp; Club en Palm Springs, California. Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n<p><strong>T\u00edtulo:<\/strong> Terapia optogen\u00e9tica MCO-010 para tratar la enfermedad de Stargardt: seguridad y eficacia hasta la semana 48 en el ensayo cl\u00ednico de fase 2a STARLIGHT<br \/>\n<strong>T\u00edtulo de la sesi\u00f3n: <\/strong>Distrofia de retina hereditaria I (ensayos de tratamiento)<br \/>\n<strong>Fecha:\u00a0<\/strong>7 de febrero de 2024<br \/>\n<strong>Tiempo:\u00a0<\/strong>6:18 p.m. a 6:25 p.m. hora del Pac\u00edfico<br \/>\n<strong>Ubicaci\u00f3n:\u00a0<\/strong>Sala principal<br \/>\n<strong>Presentador:\u00a0<\/strong>Dr. V\u00edctor Gonz\u00e1lez, Valley Retina Institute, McAllen, TX<\/p>\n<p>Durante su presentaci\u00f3n, el Dr. Gonz\u00e1lez describir\u00e1 el dise\u00f1o del ensayo y los datos de 48 semanas de STARLIGHT (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05417126?term=nanoscope&draw=2&rank=3\">NCT05417126<\/a>), el primer estudio cl\u00ednico de terapia optogen\u00e9tica para la p\u00e9rdida grave de visi\u00f3n causada por la enfermedad de Stargardt. El Dr. Gonz\u00e1lez cubrir\u00e1 las mejoras en la agudeza visual mejor corregida (BCVA) de los pacientes con STARLIGHT, medida por el gr\u00e1fico ETDRS, despu\u00e9s de una \u00fanica inyecci\u00f3n intrav\u00edtrea de MCO-010. El Dr. Gonz\u00e1lez tambi\u00e9n compartir\u00e1 sus opiniones sobre c\u00f3mo los resultados de STARLIGHT pueden informar el futuro desarrollo cl\u00ednico del programa Stargardt de Nanoscope a medida que avanza hacia la Fase 3.<\/p>\n<p><strong>Resultados clave del ensayo cl\u00ednico STARLIGHT<\/strong><\/p>\n<ul>\n<li>MCO-010 fue bien tolerado y no se mantuvieron eventos adversos graves (AAG) durante 48 semanas.<\/li>\n<li>Los pacientes con enfermedad predominantemente macular experimentaron mejoras cl\u00ednicamente significativas en la MAVC<\/li>\n<li>Se observaron mejoras en el campo visual y en los resultados informados por los pacientes (lectura y color y contraste).<\/li>\n<\/ul>\n<p><strong>Acerca de la enfermedad de Stargardt<\/strong><strong><br \/>\n<\/strong>La enfermedad de Stargardt es un trastorno ocular hereditario poco com\u00fan causado por dep\u00f3sitos de grasa en la m\u00e1cula, que provocan la p\u00e9rdida de la visi\u00f3n en el campo central. Afecta aproximadamente a entre 8.000 y 10.000 pacientes en los EE. UU., a menudo con s\u00edntomas que comienzan en la infancia o la adolescencia. Actualmente, no existen tratamientos aprobados por la FDA.<\/p>\n<p><strong>Acerca de Nanoscope Therapeutics Inc.<br \/>\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina para las que no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04945772?term=Nanoscope&draw=2\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05417126?term=nanoscope&draw=2&rank=3\">NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><strong>Contacto de inversores:<\/strong><br \/>\nSocios Argot<br \/>\n212-600-1902<br \/>\n<a href=\"mailto:PR@nanostherapeutics.com\">PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>Dallas, TX (February 7, 2024) \u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr. Victor Gonzalez will present at the 47th Annual Macula Society Meeting, taking place from Feb 7-10 at the La Quinta Resort &#038; Club in Palm Springs, California. Presentation details are as [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5648,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5646","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-07T15:10:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:22:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_MaculaSociety2024.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_MaculaSociety2024.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting\",\"datePublished\":\"2024-02-07T15:10:31+00:00\",\"dateModified\":\"2025-06-27T16:22:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/\"},\"wordCount\":394,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_MaculaSociety2024.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_MaculaSociety2024.jpg\",\"datePublished\":\"2024-02-07T15:10:31+00:00\",\"dateModified\":\"2025-06-27T16:22:09+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_MaculaSociety2024.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_MaculaSociety2024.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/07\\\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 47\u00aa Reuni\u00f3n Anual de la Sociedad de M\u00e1cula - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-02-07T15:10:31+00:00","article_modified_time":"2025-06-27T16:22:09+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_MaculaSociety2024.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_MaculaSociety2024.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting","datePublished":"2024-02-07T15:10:31+00:00","dateModified":"2025-06-27T16:22:09+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/"},"wordCount":394,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_MaculaSociety2024.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/","url":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la 47\u00aa Reuni\u00f3n Anual de la Sociedad de M\u00e1cula - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_MaculaSociety2024.jpg","datePublished":"2024-02-07T15:10:31+00:00","dateModified":"2025-06-27T16:22:09+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_MaculaSociety2024.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_MaculaSociety2024.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/07\/nanoscope-therapeutics-to-present-at-47th-annual-macula-society-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5646"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5646\/revisions"}],"predecessor-version":[{"id":9055,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5646\/revisions\/9055"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5648"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}